ES2550059T3 - Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales - Google Patents

Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales Download PDF

Info

Publication number
ES2550059T3
ES2550059T3 ES11710383.8T ES11710383T ES2550059T3 ES 2550059 T3 ES2550059 T3 ES 2550059T3 ES 11710383 T ES11710383 T ES 11710383T ES 2550059 T3 ES2550059 T3 ES 2550059T3
Authority
ES
Spain
Prior art keywords
bacillus subtilis
human
composition
prophylaxis
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11710383.8T
Other languages
English (en)
Inventor
Joseph Earl Schmidt
Desmond Rito Jimenez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer CropScience LP
Original Assignee
Bayer CropScience LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer CropScience LP filed Critical Bayer CropScience LP
Application granted granted Critical
Publication of ES2550059T3 publication Critical patent/ES2550059T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Una composición que comprende Bacillus subtilis QST713 (número de acceso de NRRL B21661) o un mutante de Bacillus subtilis QST713 que tiene todas las características identificadoras de Bacillus subtilis QST713 para su uso en mejorar la salud de un ser humano, la mejora de la salud comprende administrar al ser humano una cantidad eficaz de la composición, y en donde la composición se administra al ser humano en una cantidad eficaz para tratar un trastorno gastrointestinal, en donde el trastorno gastrointestinal se selecciona del grupo que consiste en diarrea aguda, infección asociada a Clostridium dificile, enfermedad intestinal inflamatoria, trastorno del intestino irritable, y diarrea asociada a antibióticos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8

Claims (1)

  1. imagen1
ES11710383.8T 2010-03-17 2011-03-17 Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales Active ES2550059T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31499710P 2010-03-17 2010-03-17
US314997P 2010-03-17
PCT/US2011/028755 WO2011116155A1 (en) 2010-03-17 2011-03-17 Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions

Publications (1)

Publication Number Publication Date
ES2550059T3 true ES2550059T3 (es) 2015-11-04

Family

ID=44072771

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11710383.8T Active ES2550059T3 (es) 2010-03-17 2011-03-17 Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales

Country Status (10)

Country Link
US (1) US9457054B2 (es)
EP (1) EP2547348B1 (es)
JP (1) JP5830084B2 (es)
AU (1) AU2011227226B2 (es)
DK (1) DK2547348T3 (es)
ES (1) ES2550059T3 (es)
MY (1) MY161197A (es)
NZ (1) NZ603065A (es)
PL (1) PL2547348T3 (es)
WO (1) WO2011116155A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102223809A (zh) 2008-09-17 2011-10-19 阿格拉奎斯特公司 利用枯草芽孢杆菌菌株以增强动物健康的方法
PL2547348T3 (pl) 2010-03-17 2015-11-30 Bayer Cropscience Lp Sposób zastosowania szczepu Bacillus subtilis w profilaktyce i leczeniu zaburzeń żołądkowo-jelitowych
CN103732064A (zh) 2011-05-24 2014-04-16 拜尔作物科学有限合伙公司 聚烯杀真菌剂和非核糖体肽的协同组合和相关的使用方法
WO2013126387A2 (en) * 2012-02-21 2013-08-29 Dupont Nutrition Biosciences Aps Composition
FR3007654B1 (fr) * 2013-06-27 2015-07-10 Lesaffre & Cie Composition de solute de rehydratation orale contenant des probiotiques
FR3007655B1 (fr) * 2013-06-28 2016-12-23 Lesaffre & Cie Souche bacillus subtilis pour le traitement et/ou la prevention de maladies inflammatoires chroniques
JP6440463B2 (ja) * 2013-11-15 2018-12-19 プリマハム株式会社 抗菌作用を有するバチルス・メチロトロフィカス
MX2020000182A (es) * 2017-06-30 2020-07-22 Evonik Operations Gmbh Cepa bacillus subtilis con actividad probiotica.
CA3088258A1 (en) 2018-01-24 2019-08-01 Omnigen Research, Llc Bacillus combination for administration to animals
US11278578B2 (en) * 2018-09-02 2022-03-22 Sanzyme Biologics Private Limited Combination probiotic compositions and uses thereof
BE1027162B1 (nl) * 2019-03-29 2020-11-05 My Res Comm V Bacillus coagulans en Bacillus subtilis voor de preventie en behandeling van functionele gastro-intestinale stoornissen
US11160838B2 (en) 2019-08-09 2021-11-02 Deerland Enzymes, Inc. Antifungal and antimicrobial uses of Bacillus subtilis containing compositions
GB201911925D0 (en) * 2019-08-20 2019-10-02 Sporegen Ltd Formulations for prevention or reduction of c. difficile infections

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62232343A (ja) 1986-04-01 1987-10-12 Kyodo Shiryo Kk 幼豚用配合飼料
JPS63209580A (ja) 1987-02-25 1988-08-31 Karupisu Shokuhin Kogyo Kk バチルス・ズブチリスｃ−３１０２
KR930001383B1 (ko) 1990-10-31 1993-02-27 재단법인 한국화학연구소 신규의 바실러스 서브틸리스 아종 및 이로부터 생산되는 항진균 물질 krf-001 복합체의 용도
US5785990A (en) 1995-07-10 1998-07-28 Merrick's, Inc. Feed fortifier and enhancer for preruminant calves and method of using same
JP2979294B2 (ja) 1996-10-02 1999-11-15 カルピス株式会社 鳥類卵殻強度増強剤
NZ500506A (en) 1997-05-09 2001-05-25 Agraquest Inc The Bacillus subtilis strain AQ713 useful for controlling plant diseases and corn rootworm
US6103228A (en) 1997-05-09 2000-08-15 Agraquest, Inc. Compositions and methods for controlling plant pests
US6015553A (en) 1997-08-22 2000-01-18 Agraquest, Inc. Bacillus subtilis strain for controlling insect and nematode pests
JP3260111B2 (ja) 1997-10-09 2002-02-25 伊藤忠飼料株式会社 鳥類の給餌中止時の体重減少抑制方法及び腸内有害細菌減少方法
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
JP2000166583A (ja) 1998-10-02 2000-06-20 Shin Nihonsha:Kk 枯草菌等が産生する無機物及びその酸塩と副産物及びその誘導体
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
GB0130789D0 (en) 2001-12-21 2002-02-06 King S College London Application of spores
AR040927A1 (es) 2002-04-10 2005-04-27 Cooperativas Argentinas Cooper Alimento para la crianza de vacunos neonatos y procedimiento de utilizacion.
AT413191B (de) 2002-10-11 2005-12-15 Erber Ag Futtermittel- und/oder trinkwasserzusatz für nutztiere
US7247299B2 (en) * 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
EP1472933A1 (en) 2003-05-01 2004-11-03 Chr. Hansen A/S Improving health and/or nutritional status of an aquatic animal by aid of Bacillus licheniformis
WO2005010052A2 (en) 2003-07-24 2005-02-03 Cargill, Incorporated Enhanced steep-water
RU2266747C1 (ru) 2004-03-22 2005-12-27 Кубанский государственный аграрный университет Пробиотическая композиция для животных и птицы
JP2007054041A (ja) 2005-07-29 2007-03-08 Yodorinon Kenkyusho:Kk 養鶏飼料並びに卵
US20080057047A1 (en) 2005-11-29 2008-03-06 Benedikt Sas Use of bacillus amyloliquefaciens PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
US7754469B2 (en) * 2005-11-30 2010-07-13 Agtech Products, Inc Microorganisms and methods for treating poultry
JP4968816B2 (ja) * 2006-03-08 2012-07-04 日本曹達株式会社 バチルス属細菌の芽胞形成方法
WO2007150052A1 (en) * 2006-06-23 2007-12-27 Equine Research Associates, Ltd Animal nutritional supplement and method
WO2009037242A2 (en) * 2007-09-20 2009-03-26 Basf Se Combinations comprising a fungicidal strain and an active compound
CN102223809A (zh) * 2008-09-17 2011-10-19 阿格拉奎斯特公司 利用枯草芽孢杆菌菌株以增强动物健康的方法
US8227235B2 (en) 2008-12-10 2012-07-24 Alpharma, Llc Compositions and methods for controlling diseases in animals
PL2547348T3 (pl) 2010-03-17 2015-11-30 Bayer Cropscience Lp Sposób zastosowania szczepu Bacillus subtilis w profilaktyce i leczeniu zaburzeń żołądkowo-jelitowych

Also Published As

Publication number Publication date
DK2547348T3 (da) 2015-08-24
EP2547348A1 (en) 2013-01-23
AU2011227226B2 (en) 2017-02-16
US20120328571A1 (en) 2012-12-27
JP2013522315A (ja) 2013-06-13
JP5830084B2 (ja) 2015-12-09
EP2547348B1 (en) 2015-05-20
US9457054B2 (en) 2016-10-04
WO2011116155A1 (en) 2011-09-22
AU2011227226A1 (en) 2012-11-08
PL2547348T3 (pl) 2015-11-30
NZ603065A (en) 2014-12-24
MY161197A (en) 2017-04-14

Similar Documents

Publication Publication Date Title
ES2550059T3 (es) Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales
ES2561253T3 (es) Bacterias probióticas que tienen actividad antioxidante y uso de las mismas
AR106800A1 (es) Composiciones que comprenden cepas bacterianas
CL2009001874A1 (es) Uso de bacillus subtilis qst713 nrrl b-21661 para formular una composición probiótica para un animal; y composición probiotica de bacillus subtilis qst713 nrrl b-21661.
HRP20191096T1 (hr) Sastavi koje sadrže bakterijske blautia sojeve za liječenje visceralne hipersenzitivnosti
GB2480773B (en) Compositions for the treatment of diarrhea caused by virulent E. coli infections
MX2020002727A (es) Nuevo uso para tratamiento de infecciones por clostridium difficile.
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
AR065319A1 (es) Prevencion y tratamiento de pcvd subclinica
WO2015047941A3 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
CR11723A (es) Agente para tratar enfermedad
AR078346A1 (es) Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
GT200500173A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
ECSP056189A (es) Composiciones y método para el tratamiento de infecciones en ganado vacuno y porcino
AR071968A1 (es) Uso de un oligosacarido en el tratamiento de la inflamacion intestinal
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
ES2518924T3 (es) Nuevo microorganismo y agente de control de enfermedades de las plantas usando dicho microorganismo
CO6260078A2 (es) Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros
CL2011000877A1 (es) Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino.
AR069943A1 (es) Metodo para reducir la circunferencia abdominal mediante la administracion de una bacteria bifidobacterium
ATE480247T1 (de) Immunstimulierendes mittel enthaltend eine biomasse von methanotrophem bakterium
ECSP18071568A (es) Agente microbiano de suministro directo para la prevención de una patología del camarón
MX2010003719A (es) Vacuna de mycoplasma bovis y metodos de uso de la misma.